You can be on Entrepreneur’s cover!

Pfizer-BioNTech Vaccine Is 100% Effective in Teens, Companies Claim The companies will now submit their results to the FDA, with the hope that they can vaccinate young adolescents before the start of the next school year.

By Justin Chan

entrepreneur daily

Pfizer and BioNTech jointly announced today that its coronavirus vaccine is 100% effective in teens between the ages of 12 and 15.

In a press release, the companies said that a trial involving 2,260 participants found that the efficacy rate of its Covid-19 vaccine among those in their early teens was higher than that among previous participants who were between the ages of 16 and 25.

"We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15," Pfizer CEO Albert Bourla said in a statement.

Related: Krispy Kreme Is Ready to Give You a Free Daily Doughnut for the Rest of the Year -- But Only If You've Been Vaccinated

The companies now plan to submit its results to the FDA and other regulatory agencies across the globe, with the hope that they will be able to vaccinate young adolescents before the start of the next school year.

"Across the globe, we are longing for a normal life," BioNTech CEO Ugur Sahin added. "This is especially true for our children. The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant."

While the Pfizer-BioNTech vaccine is one of three authorized vaccines in the U.S., it is the only one in the country that can be officially administered to 16- and 17-year-olds. The companies are currently testing their vaccine on children between 6 months and 11 years old.

The news comes just days after British-Swedish pharmaceutical company AstraZeneca released updated results of its own vaccine and claimed a 79% efficacy rate against symptomatic cases.

Justin Chan

Entrepreneur Staff

News Writer

Justin Chan is a news writer at Entrepreneur.com. Previously, he was a trending news editor at Verizon Media, where he covered entrepreneurship, lifestyle, pop culture, and tech. He was also an assistant web editor at Architectural Record, where he wrote on architecture, travel, and design. Chan has additionally written for Forbes, Reader's Digest, Time Out New YorkHuffPost, Complex, and Mic. He is a 2013 graduate of Columbia Journalism School, where he studied magazine journalism. Follow him on Twitter at @jchan1109.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business News

From Tom Brady to Kevin O'Leary – See Who Lost Big in the Wake of the FTX Crypto Collapse

The crash exposed an $8 billion hole in FTX's accounts, leaving investors and customers scrambling to recoup their funds.

Business News

This Highly-Debated Piece of Cinematic History Just Sold For Over $700,000 at Auction

The wood panel from "Titanic" is often mistaken as a door. Either way, he couldn't have fit. (Sorry.)

Business News

Mark Zuckerberg Says This CEO Is the 'Taylor Swift' of Tech

Meta's CEO posed with Nvidia CEO Jensen Huang on Instagram Wednesday.

Fundraising

Avoid These 9 Pitch Deck Mistakes When Asking Others For Money

Crafting an efficient pitch deck requires serious effort, but at least it's not wandering in the dark since certain rules are shaped by decades of relationships between startups and investors.